Novartis Acquires Avidity Biosciences for $12 Billion in Cash Deal

TLDR Novartis agreed to buy Avidity Biosciences for approximately $12 billion, paying $72 per share in cash, a 46% premium over Friday’s closing price The acquisition adds late-stage therapies for rare neuromuscular diseases to Novartis’s pipeline, with potential drug approvals expected by 2026 Avidity will spin off its early-stage cardiology programs into a separate publicly [...]

The post Novartis Acquires Avidity Biosciences for $12 Billion in Cash Deal appeared first on Blockonomi.